News & Updates

Novel tri-agonist confers significant gains for MASLD patients

24 Nov 2023 by

In a substudy of a phase II obesity trial, individuals with MASLD* and obesity benefited significantly from retatrutide, a once-weekly, injectable, novel synthetic molecule that has shown potent agonist action at GIP**, GLP-1***, and glucagon receptors.

Novel tri-agonist confers significant gains for MASLD patients

24 Nov 2023

Zoledronate improves BMD of children with cerebral palsy

23 Nov 2023

Twelve-month treatment with zoledronate significantly increases bone mineral density (BMD) Z-scores without affecting growth in nonambulant children with cerebral palsy (CP), reports a study. However, side effects of the first dose are common.

Zoledronate improves BMD of children with cerebral palsy

23 Nov 2023

Remnant cholesterol predicts NAFLD development

23 Nov 2023

Serum levels of remnant cholesterol may be used to assess an individual’s susceptibility to developing nonalcoholic fatty liver disease (NAFLD), independent of traditional lipid profiles, suggests a recent study.

Remnant cholesterol predicts NAFLD development

23 Nov 2023

Meal replacement-based diet beneficial to T2D patients

22 Nov 2023

A dietary pattern based on meal replacement (MR), compared with conventional diabetic diets (CDs), brings about improvements in glycaemic control and adipose indicators in patients with type 2 diabetes (T2D), according to a study.

Meal replacement-based diet beneficial to T2D patients

22 Nov 2023

Dapagliflozin offers cardioprotection in HF patients with T2D

20 Nov 2023 by

Treatment with dapagliflozin results in a lower risk of worsening heart failure (HF) or cardiovascular death and improvements in symptoms among patients with HF and type 2 diabetes (T2D), with or without neuropathy, according to a study presented at AHA 2023. However, the beneficial effects of dapagliflozin appears more evident in those with neuropathy.

Dapagliflozin offers cardioprotection in HF patients with T2D

20 Nov 2023

Healthy lifestyle helps prevent CHD despite genetic susceptibility to obesity

19 Nov 2023

People with high or medium genetic risk of abdominal obesity but who have a healthy lifestyle are less likely to develop coronary heart disease (CHD) than those with low genetic risk and an unhealthy lifestyle, a study has shown.

Healthy lifestyle helps prevent CHD despite genetic susceptibility to obesity

19 Nov 2023

Dementia risk heightened after stopping metformin treatment

18 Nov 2023 by

Metformin treatment discontinuation has been found to lead to increased incidence of dementia among older adults, and this association cannot be explained by changes in glucose control or insulin use.

Dementia risk heightened after stopping metformin treatment

18 Nov 2023

Lepodisiran lowers lipoprotein(a) concentrations in early trial

17 Nov 2023

Treatment with lepodisiran yields dose-dependent and durable reductions in serum lipoprotein(a) levels while being well tolerated, according to the results of a phase I trial.

Lepodisiran lowers lipoprotein(a) concentrations in early trial

17 Nov 2023

Real-world data back sodium zirconium cyclosilicate for hyperkalemia in HD patients

15 Nov 2023 by

The novel potassium binder, sodium zirconium cyclosilicate, has proven to be safe and effective for lowering potassium levels in the blood of Asian patients undergoing maintenance haemodialysis (HD) treatments, as shown in a study from Singapore.

Real-world data back sodium zirconium cyclosilicate for hyperkalemia in HD patients

15 Nov 2023

Original New Drug Application Approvals by US FDA (01-15 November 2023)

15 Nov 2023

New drug applications approved by US FDA as of 01-15 November 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01-15 November 2023)

15 Nov 2023

News & Updates

Filter by Specialty:

Specialty:

Novel tri-agonist confers significant gains for MASLD patients

Novel tri-agonist confers significant gains for MASLD patients

Zoledronate improves BMD of children with cerebral palsy

Zoledronate improves BMD of children with cerebral palsy

Remnant cholesterol predicts NAFLD development

Remnant cholesterol predicts NAFLD development

Meal replacement-based diet beneficial to T2D patients

Meal replacement-based diet beneficial to T2D patients

Dapagliflozin offers cardioprotection in HF patients with T2D

Dapagliflozin offers cardioprotection in HF patients with T2D

Healthy lifestyle helps prevent CHD despite genetic susceptibility to obesity

Healthy lifestyle helps prevent CHD despite genetic susceptibility to obesity

Dementia risk heightened after stopping metformin treatment

Dementia risk heightened after stopping metformin treatment

Lepodisiran lowers lipoprotein(a) concentrations in early trial

Lepodisiran lowers lipoprotein(a) concentrations in early trial

Real-world data back sodium zirconium cyclosilicate for hyperkalemia in HD patients

Real-world data back sodium zirconium cyclosilicate for hyperkalemia in HD patients

Original New Drug Application Approvals by US FDA (01-15 November 2023)

Original New Drug Application Approvals by US FDA (01-15 November 2023)